{"id":477461,"date":"2020-04-02T12:36:02","date_gmt":"2020-04-02T12:36:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=477461"},"modified":"2020-04-02T12:36:02","modified_gmt":"2020-04-02T12:36:02","slug":"hay-fever-conjunctivitis-market-size-share-trend-epidemiology-market-forecast-to-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hay-fever-conjunctivitis-market-size-share-trend-epidemiology-market-forecast-to-2030_477461.html","title":{"rendered":"Hay Fever Conjunctivitis Market Size, Share, Trend, Epidemiology & Market Forecast to 2030"},"content":{"rendered":"
\"Hay<\/a><\/p>\n
\n
Delveinsight Business Research<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Hay Fever Conjunctivitis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Hay Fever Conjunctivitis, historical and forecasted epidemiology as well as the Hay Fever Conjunctivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

Hay fever, also called allergic rhinitis or allergic rhino\u2010conjunctivitis, causes cold\u2010like signs and symptoms, such as a runny nose, itchy eyes, congestion, sneezing and sinus pressure. Seasonal Allergic Conjunctivitis is the eye component of hay fever and one of the most common eye problems. It usually happens during the spring and summer months.<\/span><\/p>\n

Seasonal allergic conjunctivitis (SAC)\/ Hay Fever Conjunctivitis is the most common type of ocular allergy. As its name suggests, it is related to specific pollen that releases spores during specific seasons: May and June (grass pollen) and August and September (ragweed pollen).<\/span><\/p>\n

The Hay Fever Conjunctivitis market report covers emerging drugs, current treatment practices, Hay Fever Conjunctivitis market share of the individual therapies, current and forecasted Hay Fever Conjunctivitis Market Size from 2017 to 2030 segmented by seven major markets. The report also provides detailed current Hay Fever Conjunctivitis treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. <\/span><\/p>\n

 <\/span><\/p>\n

Hay Fever Conjunctivitis Market Key Facts<\/strong><\/p>\n

As per the study conducted by Stacey Ackerman et. al. 2016, seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC) are the most common forms of ocular allergy subsets and they are estimated to affect 15–25% of the US population.<\/span><\/p>\n

According to the study conducted by Paulo J. Gomes et al., 2015, like all allergic diseases, SAC has seen a worldwide trend towards increased prevalence over the past few decades. Increase in SAC in children has been well documented by the International Study of Asthma and Allergies in Childhood (ISAAC).<\/span><\/p>\n

As per the study conducted by Andrea Leonardi et al., titled “Epidemiology of allergic conjunctivitis: clinical appearance and treatment patterns in a population\u2010based study”, SAC was estimated to be the most frequent ocular allergies form. In a single tertiary centre cohort study in Japan, among a total of 1079 ocular allergies cases, SAC cases were estimated to be 81.2%. [2015]<\/span><\/p>\n

 \"\"<\/span><\/p>\n

Visit For Sample Pages: <\/strong><\/p>\n

https:\/\/www.delveinsight.com\/sample-request\/hay-fever-conjunctivitis-market<\/a><\/p>\n

 <\/strong><\/p>\n

Key Benefits of Hay Fever Conjunctivitis Market Report<\/strong><\/p>\n

Hay Fever Conjunctivitis market report provides an in-depth analysis of Hay Fever Conjunctivitis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.<\/span><\/p>\n

The Hay Fever Conjunctivitis market report will help in developing business strategies by understanding the Hay Fever Conjunctivitis Market trends & developments, key players and future market competition that will shape and drive the Hay Fever Conjunctivitis market in the upcoming years.<\/span><\/p>\n

The Hay Fever Conjunctivitis market report covers Hay Fever Conjunctivitis current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.<\/span><\/p>\n

The report provides a detailed assessment of the Hay Fever Conjunctivitis market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. <\/span><\/p>\n

 <\/span><\/p>\n

Hay Fever Conjunctivitis Market<\/a><\/p>\n

The Hay Fever Conjunctivitis market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Hay Fever Conjunctivitis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. <\/p>\n

 The report gives a thorough detail of Hay Fever Conjunctivitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. <\/p>\n

 <\/p>\n

Hay Fever Conjunctivitis Epidemiology<\/a><\/p>\n

The Hay Fever Conjunctivitis epidemiology section covers insights about historical and current Hay Fever Conjunctivitis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.<\/span><\/p>\n

 It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  <\/span><\/p>\n

 <\/span><\/p>\n

Hay Fever Conjunctivitis Drugs Uptake and Key Market Players<\/a><\/p>\n

Hay Fever Conjunctivitis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hay Fever Conjunctivitis market or expected to get launched in the market during the study period. The analysis covers Hay Fever Conjunctivitis market uptake by drugs; patient uptake by therapies; and sales of each drug.    <\/span><\/p>\n

Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. <\/span><\/p>\n

Launch of emerging therapies in such as gpASIT (ASIT Biotech), Budesolv (Marinomed Biotech), Reproxalap Ophthalmic Solution (Aldeyra Therapeutics) and REGN5713\u20105714\u20105715 (Regeneron Pharmaceuticals) are expected to significantly impact the <\/span>Hay Fever Conjunctivitis market<\/span> during the study period (2017–2030).<\/span><\/p>\n

Some of the key players, such as Aldeyra Therapeutics, ASIT Biotech, Marinomed Biotech, Regeneron etc. are involved in developing <\/span>therapies for Hay Fever Conjunctivitis<\/span>.<\/span><\/p>\n

 <\/span><\/span><\/p>\n

Table of Contents<\/strong><\/p>\n

1. Key Insights<\/span><\/p>\n

2. Executive Summary <\/span><\/p>\n

3. Hay Fever Conjunctivitis Competitive Intelligence Analysis<\/span><\/p>\n

4. Hay Fever Conjunctivitis Market Overview at a Glance<\/span><\/p>\n

5. Hay Fever Conjunctivitis Disease Background and Overview<\/span><\/p>\n

6. Hay Fever Conjunctivitis Patient Journey<\/span><\/p>\n

7. Hay Fever Conjunctivitis Epidemiology and Patient Population<\/span><\/p>\n

8. Hay Fever Conjunctivitis Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n

9. Hay Fever Conjunctivitis Unmet Needs<\/span><\/p>\n

10. Key Endpoints of Hay Fever Conjunctivitis Treatment<\/span><\/p>\n

11. Hay Fever Conjunctivitis Marketed Products<\/span><\/p>\n

12. Hay Fever Conjunctivitis Emerging Therapies<\/span><\/p>\n

13. Hay Fever Conjunctivitis Seven Major Market Analysis<\/span><\/p>\n

14. Attribute Analysis<\/span><\/p>\n

15. Hay Fever Conjunctivitis Market Outlook (7 major markets)<\/span><\/p>\n

16. Hay Fever Conjunctivitis Access and Reimbursement Overview<\/span><\/p>\n

17. KOL Views on the Hay Fever Conjunctivitis Market.<\/span><\/p>\n

18. Hay Fever Conjunctivitis Market Drivers<\/span><\/p>\n

19. Hay Fever Conjunctivitis Market Barriers<\/span><\/p>\n

20. Appendix<\/span><\/p>\n

21. DelveInsight Capabilities<\/span><\/p>\n

22. Disclaimer<\/span><\/p>\n

 <\/span><\/p>\n

About<\/strong> <\/span>DelveInsight<\/a><\/p>\n

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/span><\/p>\n

 <\/span><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Anuj Rawat
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Delveinsight Business Research DelveInsight’s “Hay Fever Conjunctivitis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Hay Fever Conjunctivitis, historical and forecasted epidemiology as well as the Hay Fever Conjunctivitis market trends in the United … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-477461","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/477461","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=477461"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/477461\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=477461"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=477461"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=477461"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}